FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Deep mycosis mimicking cutaneous squamous cell carcinoma
1368PDF: 633HTML: 86 -
Taxane-induced morphea in a patient with CREST syndrome
2149PDF: 598HTML: 1193 -
Severe scratcher-reaction: an unknown health hazard?
1754PDF: 892HTML: 676 -
23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*1, Teresa Amaral*2, Piotr Rutkowski*3, Marie-Lena Rasch2, Naima Benannoune4, Patricio Serra5, Maria Grazia Vitale6, Diana Giannarelli7, Ana Maria Arance8, Eva Munoz Couselo9, Bart Neyns10, Iris Dirven11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele Del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan5, Caroline Robert24, Georgina V. Long22, Paolo A. Ascierto6, Mario Mandalà25 | 1Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; 2Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Gustave Roussy Cancer Campus, Villejuif, France. 5The University of Manchester, Manchester, UK. 6Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; 7Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 8Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; 9Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; 10Department of Medical Oncology, UZ Brussel, Brussels, Belgium. 11Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; 12Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. 13Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. 14IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; 15Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 16IEO European Institute of Oncology, IRCCS, Milan, Italy. 17Department of Dermatology, University of Turin, Turin, Italy. 18University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; 19Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. 20Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 21Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; 22Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; 23Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 24Gustave Roussy and Paris-Saclay University, Villejuif, France; 25Unit of Medical Oncology, University of Perugia, Perugia, Italy. § on behalf of the Italian Melanoma Intergroup - IMI.
290 -
Rituximab for linear immunoglobulin A bullous dermatosis
1353PDF: 558HTML: 32 -
Autoinflammatory diseases: what is behind them and what is new?
1779PDF: 560HTML: 138 -
